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Immunization with a tumor-associated CTL epitope
plus a tumor-related or unrelated Th1 helper
peptide elicits protective CTL immunity
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Immunization with cytotoxic T cell epitope SPSYVYHQF (AH1), derived from MuLV gp70
envelope protein expressed by CT26 tumor cells, does not protect BALB/c mice against
challenge with CT26 tumor cells. By contrast, immunization with AH1 plus T helper peptides
OVA(323–337) or SWM(106–118) eliciting Th1 and Th0 profiles, protected 83% and 33% of
mice, respectively. Interestingly, immunization with AH1 plus both helper peptides reverted
the efficacy to 33%. We identified the endogenous T helper peptide p(320–333) from gp70
which elicits a Th1 profile and is naturally processed. As for OVA(323–337), immunization
with p(320–333) alone did not protect against tumor challenge. However, p(320–333) plus
AH1 protected 89% of mice at day 10 after vaccination. Only 20% of mice vaccinated with
AH1 + OVA(323–337) or AH1 + p(320–333) were protected when challenged 80 days after
immunization. Treatment with OVA(323–337) or with p(320–333) around established tumors
delayed tumor growth. Our results show that tumor-related as well as tumor-unrelated but
strong Th1 peptides may be useful for inducing CTL responses in tumor immunotherapy.
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1 Introduction
Cytotoxic T lymphocytes (CTL) play an important role in
antitumor immune responses [1, 2]. These cells
recognize eight- to ten-amino acid-long peptides
derived from tumor antigens presented by major histo-
compatibility complex (MHC) class I molecules at the
surface of tumor cells. It is well documented that induc-
tion of CTL usually requires help from CD4+ T helper lym-
phocytes [3–6], which recognize peptides presented by
MHC class II molecules. Thus, it is conceivable that the
lack of a competent T helper response induced by tumor
antigens might result in tumor growth. Immunization with
synthetic peptides containing T helper cell determinants
(THd) and T cytotoxic cell determinants (TCd) has
allowed the induction of CTL responses against different
antigens [3–7]. THd presented by class II molecules may
elicit Th0, Th1 or Th2 cytokine profiles [8–10], but, as
shown in recent studies, THd eliciting a Th1 cytokine
profile induce CTL more efficiently than those eliciting
Th2 or Th0 profiles [11, 12]. For the purpose of CTL
induction, THd may originate from an exogenous protein
not related to the tumor antigens or from an endogenous
tumor antigen. However, because immunization with an
endogenous tumor-specific THd alone was able to par-
tially protect mice from challenge with MHC class II-
negative virus-induced tumor cells [13], it is likely that an
endogenous THd might be more suitable than an exoge-
nous THd (from a protein not related to the tumor) for
antitumor therapy. This prompted us to evaluate the
relative efficacy of endogenous and exogenous THd to
induce protective antitumor immune responses. To
address this question we used as model TCd the peptide
SPSYVYHQF (from now on AH1) derived from MuLV
gp70 envelope protein expressed by CT26 cells and pre-
sented by H-2Ld MHC class I molecules [14]. Immuniza-
tion of BALB/c mice with AH1 is unable to induce a pro-
tective response against challenge with CT26 tumor cells
[14]. To provide T cell help for CTL induction, we tested
exogenous Th0 and Th1 peptides as well as an endoge-
nous Th1 peptide from gp70 antigen expressed by CT26
tumor cells, which was identified and characterized in
the present work. The relative efficacy of these immuni-
zation strategies was tested by challenging vaccinated
mice with MHC class II-negative CT26 tumor cells. We
report here that immunization with certain combinations
of THd and THc induce protective immunity against s.c.
or i.v. challenge with CT26 tumor cells.
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Fig. 1. Evolution of tumor growth after challenge with CT26 tumor cells in groups of BALB/c mice immunized with different pep-
tide combinations. As a control, a group of mice was immunized with IFA alone. Ten days later, animals were challenged by s.c.
injection with 5×105 CT26 tumor cells. (A) Average tumor size was expressed as the square value of the smallest diameter of the
tumor, times the value of its largest diameter. (B) Kaplan-Meier plots of the mice survival after challenge with CT26 tumor cells.
Table 1. Cytokine profile elicited after immunization of BALB/c mice with exogenous helper peptides OVA(323–337),
SWM(106–118) or T cytotoxic determinant AH1 from CT26a)
Peptide IL-2 (mU/ml)a) IFN- + (pg/ml)c) IL-4 (mU/ml)c) Cytokine profile
In vitro treatmentb)
None Anti-CD4 Anti-CD8
OVA(323–337) 47 21 62 624 X 5 Th1
SWM(106–118) 80 17 72 1,117 398 Th0
AH1 3 NT NT X 36 X 5 –
a) Mice were immunized with 50 ? g peptide emulsified in IFA. Ten days after lymph node cells were cultured in the presence or
absence of peptide and cytokines were measured.
b) Anti-CD4 or anti-CD8 mAb (100 ? g) were added to the culture to study their effect in IL-2 production.
c) IL-2, IFN- + or IL-4 production in the absence of peptide was always below 5 mU/ml, 50 pg/ml and 25 mU/ml, respectively.
2 Results
As mentioned above, immunization of mice with TCd
peptide AH1 from gp70 protein of CT26 tumor cells is
unable to protect mice from challenge with these cells.
For this reason we decided to study whether immuniza-
tion of mice with AH1 plus different types of THd pep-
tides might be more efficient. In the first part of this work
we study exogenous THd peptides. In the second part,
we identify an endogenous THd from gp70 and compare
its efficacy with the group of exogenous THd peptides.
2.1 Cytokine profiles induced by exogenous
T helper determinants following
immunization
To study the effect of different cytokine profiles induced
by THd in antitumor CTL responses, we measured IL-2,
IFN- + and IL-4 induced by OVA(323–337) from chicken
ovalbumin and by SWM(106–118) from sperm whale
myoglobin [15, 16]. As a control, we also measured these
cytokines after immunization with the immunodominant
TCd peptide AH1 from gp70 presented by class I mole-
cules H-2Ld [14]. As shown in Table 1 and reported ear-
lier [12], OVA(323–337) and SWM(106–118) elicit Th1 and
Th0 cytokine profiles, respectively, in BALB/c mice.
Addition of anti-CD4 but not anti-CD8 monoclonal anti-
bodies strongly reduced IL-2 production, indicating that
CD4 cells are responsible for cytokine production. How-
ever, AH1 induced very low amounts of IL-2 and was
unable to induce significant levels of IFN- + or IL-4, indi-
cating its inability to function as a THd.
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2.2 Efficacy of different peptide combinations to
protect mice from CT26 tumor cell challenge
Since from a previous publication [12] we knew that co-
immunization of THd OVA(323–337) or SWM(106–118)
with a TCd was able to induce a CTL response, we
tested whether this strategy could be used to protect
animals from challenge with CT26 tumor cells. In a first
experiment, groups of BALB/c mice were immunized
with different THd plus the TCd AH1. These groups were:
AH1 + OVA(323–337), AH1 + SWM(106–118), AH1 alone,
OVA(323–337) alone, or IFA alone. The dose of THd used
was that tested for cytokine production. When lower
doses of THd were tested for cytokine production, lower
levels of cytokines were elicited but the profiles remained
the same as for the higher doses (data not shown).
Animals were then challenged with CT26 tumor cells
10 days after immunization. Co-immunization with AH1
+ THd OVA(323–337) prevented tumor growth in eight of
nine mice (89%), whereas only three of nine (33%) were
protected when using SWM(106–118) as THd (p X 0.05).
By contrast, immunization with AH1 alone only delayed
tumor growth, whereas immunization with OVA(323–337)
alone, or IFA alone, were without effect (Fig. 1). Indeed,
all mice immunized with OVA(323–337) alone, AH1
alone, or IFA alone, developed lethal tumors. Because
high levels of IL-4 induced after immunization might be
detrimental for CTL induction, we addressed the ques-
tion of whether the simultaneous immunization with
exogenous Th0 and Th1 peptides plus a TCd might be
less efficient than the immunization with only the Th1 and
the TCd. As indicated in Table 2, we vaccinated mice
Table 2. Efficacy of vaccination of BALB/c mice using dif-
ferent peptide combinations
Vaccination mixturea) Percentage of
protectionb)
1. AH1 + OVA(323–337) 8/9 (88.9 %)
2. AH1 + SWM(106–118) 3/9 (33 %)
3. AH1 + OVA(323–337) + SWM(106–118) 3/9 (33 %)
4. AH1 0/9 (0 %)
5. IFA 0/9 (0 %)
a) Mice were vaccinated with the peptide mixtures shown
and challenged with CT26 tumor cells 10 days after
vaccination. Protection is expressed as the percentage of
mice bearing no tumors.
b) p X 0.0004 when comparing group 1 versus 5;
p X 0.05 when comparing group 1 versus 2;
non-statistically significant when comparing groups 2 or
3 versus group 5.
with AH1 + OVA(323–337), AH1 + SWM(106–118), AH1 +
the mixture of SWM(106–118) and OVA(323–337), AH1
alone or IFA alone. This experiment shows that in the first
case three of nine (89%) mice were protected, whereas
in the second and third cases, only three of nine (33%) of
mice were protected, indicating that the presence of a
Th0 helper peptide may have a deleterious effect on
the efficacy of vaccination. No protection was observed
after immunization with AH1 alone or IFA alone. It is inter-
esting to note that cells from mice immunized with
AH1 + OVA(323–337) + SWM(106–118), when stimulated
with OVA(323–337) alone, SWM(106–118) alone or
OVA(323–337) + SWM(106–118) gave 1,800, 400 and
500 pg IFN- + /ml, respectively, suggesting that the pres-
ence of the Th0 peptide lowers the level of IFN- + produc-
tion expected for the Th1 peptide.
2.3 Protective immunity induced by
immunization with peptide combinations
is mediated by CD8+ CTL
As shown in Fig. 2A, lymph node cells from mice immu-
nized with AH1 + OVA(323–337) but not with AH1 alone,
were able to lyse P815 target cells pulsed with AH1.
However, some background lysis was observed against
unpulsed P815 cells. This background was not detected
when using other peptide combinations that were not
effective against tumor growth (data not shown). Since it
has been reported by Huang et al. [14] that P815 cells
express gp70, we believe that this background is related
to the expression of this protein. CD8 activity was also
measured using an IFN- + production assay. This experi-
ment showed that only lymphocytes from mice immu-
nized with AH1 + OVA(323–337) but not with AH1 alone
or AH1 + SWM(106–118) were able to produce signifi-
cant amounts of IFN- + in the presence of AH1 (Fig. 2B).
Interestingly, no background noise was observed under
these conditions, probably because in this assay APC
are spleen cells not expressing gp70. Characterization of
the effector cells induced in lymph nodes after immuni-
zation with AH1 + OVA(323–337) showed that they were
CD8+ (Fig. 2C). To confirm that CD8+ CTL were responsi-
ble for in vivo protection against tumor challenge, we
studied the efficacy of immunizations in CD4+ or CD8+
cell-depleted animals. As expected, all mice depleted of
CD8+ cells and immunized with OVA(323–337) + AH1
developed terminal tumors, suggesting that induced
CTL are responsible of tumor protection (Table 3). Inter-
estingly, mice depleted of CD4+ cells and immunized
with OVA(323–337) + AH1 or with AH1 alone were fully
protected from tumor challenge.
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Fig. 2. Characterization of the CTL response induced after
peptide immunization. (A) Specific lysis of P815 cells pulsed
(filled bars) or unpulsed (empty bars) with peptide AH1 by
CTL induced after immunization with AH1 alone or AH1 plus
OVA(323–337) or AH1 plus SWM(106–118). (B) IFN- + pro-
duction of spleen cells from immunized mice after in vitro
restimulation in the presence or absence of AH1. (C) Effect
of anti-CD4 and anti-CD8 antibodies on the CTL induced
after immunization with AH1 plus OVA(323–337). Lymph
node cells were incubated with target cells at a ratio of 30:1
with or without 100 ? g/ml of anti-CD4 or anti-CD8 monoclo-
nal antibodies.
2.4 Identification and characterization of an
endogenous Th1 peptide from gp70
Ossendorp et al. [13] reported that vaccination with a
THd from a tumor antigen was able to protect around
40% of mice to challenge with tumor cells. This protec-
tion increased to around 90% when a THd and a TCd
from the tumor antigen were used. By contrast, immuni-
zation with the TCd plus an exogenous THd was less
efficient than immunization with the endogenous THd
alone [13]
Because our results show that co-immunization with the
tumor TCd + OVA(323–337) was able to protect BALB/c
Table 3. Effect of in vivo depletion of CD4+ or CD8+ cells on
the induction of antitumor protective immune responsesa)
Immunized with In vivo treatment Percentage of
protection
AH1 + OVA(323–337) anti-CD4 6/6 (100 %)
anti-CD8 0/6 (0 %)
AH1 anti-CD4 6/6 (100 %)
anti-CD8 0/6 (0 %)
None anti-CD4 (0/6 (0 %)
anti-CD8 0/6 (0 %)
a) Mice were depleted of CD4+ or CD8+ cells in vivo and
immunized with peptide mixtures shown. Ten days after
immunization, mice were challenged s. c. with 5 × 105
CT26 tumor cells. Protection is expressed as the
percentage of mice bearing no tumors.
Table 4. Cytokines induced after immunization of BALB/c
mice with putative binder peptides to I-Ad or I-Ed molecules
from gp70 tumor antigen
Peptide IL-2 (mU/ml) IFN- + (pg/ml) IL-4 (mU/ml)
p (33–46) 91 X 50 X 50
p (109–122) 160 X 50 X 50
p (142–155) 18 X 50 X 50
p (144–157) 5 X 50 X 50
p (153–166) 50 X 50 X 50
p (155–168) 1 X 50 X 50
p (177–190) 70 X 50 X 50
p (260–273) 5 X 50 X 50
p (289–302) 127 X 50 X 50
p (320–333) 183 970 X 50
p (324–337) 32 X 50 X 50
a) Mice were immunized with 50 ? g peptide emulsified in
IFA. Ten days after lymph node cells were cultured in the
presence or absence of peptide and cytokines were
measured as described in Sect. 4.
mice, we decided to compare the efficacy of this exoge-
nous THd with an endogenous THd from gp70 tumor
antigen. Since no sequences with THd character have
been previously identified within gp70, we scanned the
sequence of gp70 (described in [17]) using the algorithm
of Sette et al. [18] to predict I-Ad- and I-Ed-restricted T
helper peptides. This afforded the 11 peptides from
Table 4, which were synthesized and their helper activity
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Fig. 3. Characterization of the helper response from
p(320–333). Mice were immunized with p(320–333) or with
IFA alone. (A) Lymph nodes cells stimulated with or without
p(320–333) in the presence of different antibodies. (B)
Lymph node cells were stimulated for 48 h with dilutions of
CT26 cell lysate and IFN- + was measured by ELISA. (C) Pro-
duction of IFN- + after stimulation with p(320–333) of spleen
cells from mice that had rejected CT26 induced tumors due
to intratumor administration of dendritic cells engineered to
produce IL-12.
tested in our animal model. For this purpose, BALB/c
mice were immunized with 60 ? g of these peptides in
IFA. Lymph nodes obtained at day 10 were cultured in
the presence or absence of peptides and IL-2, IFN- + and
IL-4 production was then measured. Among all the pep-
tides tested, p(109–122), p(289–302) and p(320–333)
induced the highest levels of IL-2, but only p(320–333)
(LVQFIKDRISVVQA) was able to induce high levels of
IFN- + . It is noteworthy that none of these peptides
induced detectable levels of IL-4. Addition of anti-CD4
but not anti-CD8 monoclonal antibodies to the culture in
vitro of spleen cells from mice immunized with
p(320–333), abrogated IFN- + production, indicating
that CD4+ cells are responsible for IFN- + production
(Fig. 3A).
To study whether p(320–333) was presented by APC
after natural processing of gp70 antigen, we immunized
mice with p(320–333) in IFA. After 10 days, lymph node
cells were cultured in the presence of different concen-
trations of a CT26 cell lysate and IFN- + production was
measured after 48 h. Fig. 3B shows that this lysate is
able to stimulate IFN- + production in vitro by lymph node
cells from p(320–333) immunized animals. By contrast,
no IFN- + production was detected after in vitro stimula-
tion of lymph node cells from animals immunized with
IFA alone. Moreover, spleen cells from mice that had
rejected CT26 induced tumors after intratumor adminis-
tration of dendritic cells engineered to produce IL-12, as
previously described by our laboratory [19] produced
IFN- + when stimulated with p(320–333) (Fig. 3C). Results
from Table 4 and Fig. 3 taken together show that
p(320–333) is naturally presented by APC and elicits a
Th1 cytokine profile. For this reason we tested this pep-
tide in protection experiments, either when used alone or
plus AH1. Immunization with AH1 + p(320–333) was able
to protect BALB/c mice (9/9 mice) from challenge with
CT26 tumor cells, as compared to eight of nine mice
after immunization with AH1 + OVA(323–337) (Fig. 4). As
expected, in vivo depletion of CD8+ cells before chal-
lenge, completely abrogated this protection (not shown).
As found for OVA(323–337) alone, immunization with
p(320–333) alone was unable to protect any of the immu-
nized mice (0/9).
2.5 Effect of peptide vaccination on the
protection against lung metastases
The efficacy of vaccination with AH1 plus either
OVA(323–337) or p(320–333) to protect against lung
metastases after i.v. injection of 1×105 CT26 tumor cells
is shown in Fig. 5. The degree of protection using either
peptide was not significantly different but significantly
lower than in the group of non-vaccinated mice
(p X 0.001).
2.6 Comparison of efficacy of exogenous and
endogenous Th1 peptides on the induction of
long-term antitumor protection
To study if memory induced with endogenous helper
peptide p(320–333) was longer than the one induced
with exogenous helper peptide OVA(323–337), we immu-
nized 15 mice with AH1 + p(320–333) or with AH1 +
OVA(323–337). Five mice from each group were killed at
day 80 to measure cytokine production against the pep-
tides used for immunization. No IL-2 nor IFN- + produc-
tion could be detected in either group under the stimuli
of peptides (not shown). The remaining 10 animals from
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Fig. 4. Evolution of tumor growth after challenge with CT26 cells in groups of nine BALB/c mice immunized with peptide combi-
nations shown. At 10 days after immunizations, animals were challenged by s.c. injection with 5×105 CT26 tumor cells. (A) Aver-
age tumor size was expressed as the square value of the smallest diameter of the tumor, times the value of its largest diameter.
(B) Kaplan-Meier plot of mice survival after challenge with CT26 tumor cells.
Fig. 5. Protection against lung cancer metastases by vacci-
nation with peptides. Mice were challenged intravenously
with 1×105 CT26 tumor cells 10 days after vaccination.
Metastases were counted 20 days after tumor challenge.
each group were challenged with CT26 tumor cells
80 days after immunization. No differences in protection
were observed between both groups. Indeed, only 2 ani-
mals (20%) from each group were still protected against
tumor growth (Table 5 ).
2.7 Treatment of established tumors by
immunization with peptides
To test the efficacy of peptides to treat established
tumors, we inoculated mice with CT26 tumor cells, and
once tumors of around 5 mm were established, peptides
were administered in IFA around the tumor. Five groups
of mice were treated: (a) with IFA alone, (b) with AH1
+OVA (323–337), (c) with AH1 + p(320–333), (d) with
OVA(323–337) alone, and (e) with p(320–333) alone. As
shown in Fig. 6, tumor growth at day 14 after treatment,
was significantly delayed when administering p(320–333)
alone (p=0.0098). A delay in tumor growth, although non-
significant (p=0.055), was observed when OVA(323–337)
was administered. Tumors continued to develop after
day 14, except in one mice per group in those im-
munized with p(320–333) alone and another with
OVA(323–337) alone, where the tumor was rejected.
Table 5. Efficacy of endogenous versus exogenous helper
peptides for the protection against challenge with CT26 at
different time points
Immunized witha) Day of challenge
with CT26 tumor
cells
Number of mice
Protected/Total
AH1 + OVA(323–337) 10 15/18b)
AH1 + p(320–333) 10 16/18b)
AH1 10 0/9
AH1 + OVA(323–337) 80 2/10
AH1 + p(320–333) 80 2/10
a) BALB/c mice were immunized at day 0 with peptide
combinations shown and were challenged with CT26
tumor cells at days indicated.
b) The number correspond to the sum of two groups of
nine mice immunized in two independent experiments.
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Fig. 6. Treatment of established tumors by immunization
with different peptide combinations. Groups of five to eight
mice were inoculated with 5×105 CT26 tumor cells. When
tumor size reached a diameter of around 5 mm, mice were
immunized around the tumor area with IFA alone or the com-
binations of peptides shown. Tumor size was expressed as
the square value of the smallest diameter of the tumor, times
the value of its largest diameter. Values shown correspond to
the size of tumors 14 days after treatment.
3 Discussion
CTL play an important role in the protection against
tumor growth, and for this reason, methods aiming at
CTL induction are of paramount importance for antitu-
mor therapy. This induction takes place via the help from
T helper lymphocytes that are activated when THd pep-
tides are presented by MHC class II molecules. In the
present publication we study different types of THd pep-
tides and compare their efficacy in providing T cell help
for the induction of protective antitumor CTL responses.
It has been reported that immunization with peptide AH1
emulsified in IFA or with peptide-pulsed dendritic cells is
unable to induce CTL [14]. This lack of CTL response
was also confirmed in the present study. Moreover, since
no production of IL-2, IFN- + or IL-4 was observed after
vaccination with AH1 in IFA, we attributed this lack of
response to the absence of T cell help. For this reason,
based on previous results from our group [5, 12] as well
as from others [3, 4, 6, 7, 20], we speculated that immu-
nization with AH1 plus an efficient THd might induce a
protective CTL response. As expected, it was found that
co-immunization of this peptide and the exogenous THd
OVA(323–337), inducing a Th1 cytokine profile (Table 1),
protected 15/18 (83%) mice against challenge with CT26
tumor cells (Table 5).
Interestingly, depletion of CD8+ cells, but not CD4+ cells,
abrogated the protective effect of peptide immuniza-
tions. At first sight, this data might suggest that CD4+
cells are not relevant for protection. However, as it has
been described recently [21] in vivo CD4+ cell depletion
also depletes CD4+ NKT cells responsible for the repres-
sion of immunosurveillance. It is very interesting to note
that immunization with AH1 alone in the absence of CD4+
cells efficiently protected mice from tumor challenge
(Table 3). We are actively working to characterize this
phenomenon.
We have recently reported [12] that peptide
SWM(106–118), eliciting a Th0 cytokine profile, is less
efficient than Th1 peptides in inducing CTL responses.
We show here that vaccination with a TCd in conjunction
with a Th1 plus a Th0 helper peptides [OVA(323–337)
and SWM(106–118), respectively] is less efficient than
vaccination with the TCd plus OVA(323–337) (Table 2).
This detrimental effect is probably related to the drop in
IFN- + production observed in vitro when both Th1 and
Th0 peptides are present. This observation is in line with
the recent publication of Song et al. [22] showing that the
simultaneous use of a vector expressing carcinoem-
bryonic antigen and a vector expressing IL-4 reduced
CTL activity and resistance to tumor challenge. These
findings may be important for vaccine design when using
combinations of THd and TCd peptides. Using IL-4-
deficient mice Schuler at al [23] have shown that IL-4 is
required for the generation of Th1-associated CTL-
mediated tumor immunity. To reconcile this observation
with our data it could be postulated that, although IL-4
may be necessary, high levels of this cytokine may have
detrimental effects on CTL induction.
Ossendorp et al. [13] reported that vaccination of
C57BL/6 mice with the endogenous env-H19 THd alone
protected around 40% of mice against challenge with
RMA tumor cells. Enhanced protection (70%) was
achieved after immunization with this helper peptide plus
the TCd env-Kb8. Moreover, immunization of C57BL/6
mice with env-Kb8 CTL epitope plus OvaH [OvaH is iden-
tical to OVA(323–337) used by us, but two amino acids
longer] protected only 10% of mice. Since OvaH binds to
I-Ab molecules (C57BL/6 mice) four times less efficiently
than to I-Ad molecules (BALB/c mice) [24], it is likely that
the higher affinity of OVA(323–337) for I-Ad may explain
why, in our system, immunization with OVA(323–337)
plus AH1 is able to efficiently protect BALB/c mice from
CT26 tumor challenge.
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In agreement with the work of Ossendorp et al. [13]
immunization with the exogenous THd OVA(323–337)
alone did not protect mice from tumor challenge. Since
immunization with an endogenous THd from a tumor
antigen was able to protect against challenge with tumor
cells [13, 25], we carried out experiments and identified
the endogenous Th1 peptide p(320–333) from gp70. We
then immunized mice with p(320–333) plus AH1 and
found that 16/18 (89%) mice were protected against
challenge with CT26 tumor cells (Table 5), showing that
p(320–333) provides efficient T cell help for CTL in-
duction. Also, co-immunization of AH1 with either
p(320–333) or OVA(323–337) protected against lung
metastases after i.v. injection of tumor cells, demonstrat-
ing that these protocols are effective even under more
invasive conditions of challenge with tumor cells (Fig. 5).
As opposed to Ossendorp et al. and Miyazawa et al. [13,
25], our endogenous THd alone did not protect mice
from tumor challenge, suggesting that our endogenous
helper peptide is less efficient than those used by these
authors. By contrast, our work shows that efficient pro-
tection against challenge with CT26 tumor cells can be
achieved by co-immunization with the TCd AH1 plus
the endogenous Th1 peptide p(320–333), but also, and
most importantly, with exogenous tumor-unrelated Th1
peptide OVA(323–337). Because finding a convenient
endogenous Th1 helper peptide from tumor antigens in
the context of a given class II molecule might not be
straightforward, the use of an exogenous THd, is an
alternative to be seriously considered. This THd should
elicit a strong Th1 cytokine response in the context of the
class II molecule of the vaccinee. Helper and cytotoxic
memories might be kept high by repeated immunizations
with the exogenous THd plus one or more TCd. This
strategy might prevent the onset of metastases after sur-
gical intervention or therapeutic vaccination. An advan-
tage of this strategy would be that only a few Th1 pep-
tides would need to be developed to cover all possible
HLA class II restrictions. Alternatively, as suggested by
Alexander et al. [24], a promiscuous helper peptide could
be used, provided that this peptide was indeed a Th1
peptide in the context of the class II molecule of our
interest.
Therapeutic immunizations of mice bearing established
tumors with endogenous or exogenous helper peptides,
were largely unsuccessful. With the exception of two
complete tumor regressions observed after immuniza-
tion with p(320–333) alone and OVA(323–337) alone, only
minor, but statistically significant, delays in tumor pro-
gression were observed (Fig. 6). The mechanism by
which an exogenous Th peptide can favor the control of
established tumor growth it is not clear. However, as
described [26], immunization with a good helper peptide
may awake the effect of a poorer helper peptide. In our
study, the cytokines induced by OVA(323–337) might
awake tumor-specific helper and CTL which remained
inactive even in the presence of tumor cells. The effi-
ciency of peptide immunization in the treatment of
established tumors, might perhaps be improved using
Th1 peptides inducing higher levels of cytokines, and
concomitantly chemokines capable of attracting acti-
vated T lymphocytes to the tumor site.
In conclusion, our results in conjunction with those from
others [11, 13, 25] suggest that Th1 peptides provide
efficient help for CTL induction against tumors. Also, Th0
peptides when present in immunization mixtures, may
diminish the efficient help of Th1 peptides. Moreover,
and most important, because after challenge with tumor
cells, endogenous but not exogenous Th1 peptides, may
be activated to provide T cell help, these peptides should
be favored for peptide-based cancer therapy. However,
as discussed above, under special circumstances, the T
cell help could be provided by an exogenous THd elicit-
ing a Th1 cytokine profile. Last, but not least, it seems
advisable that peptide vaccines providing long-lasting
immunity should contain several Th1 THd as well as sev-
eral TCd from one or more antigens from the tumor.
4 Materials and methods
4.1 Peptides
Peptides were synthesized by the solid- phase method of
Merrifield [27] using a manual multiple solid-phase peptide
synthesizer as described in [12]. At the end of the synthesis,
peptides were cleaved, deprotected, and washed six times
with diethyl ether. They were lyophilized and analyzed by
HPLC. The purity of peptides was above 80% as judged by
HPLC.
4.2 Mice
Six-week-old female BALB/c mice were purchased from
IFFA Credo (Barcelona, Spain). They were hosted in appro-
priate animal care facilities and handled following institu-
tional guidelines.
4.3 Immunization and measurement of CTL response
Mice were immunized by s.c. injection at the base of the tail
and footpads with 60 ? g peptide emulsified in IFA. For
immunizations using a THd and a TCd mixture, 60 ? g of
each peptide was injected. For CTL measurements, animals
were killed 10 days after immunization and their lymph
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nodes removed. Cells (8×106/well) were restimulated in vitro
in 24-well plates in 2 ml of culture medium (RPMI 1640 sup-
plemented with 10% fetal calf serum, 2 mM glutamine, peni-
cillin 100 U/ml, streptomycin 100 ? g/ml and 5×10–5 M
2-mercaptoethanol) with 5 ? g/ml of peptide. Cytotoxic activ-
ity was measured 5 days after initial culture using the
51Cr-release assay as described [12].
4.4 Immunization for cytokine measurement
Mice were immunized by s.c. injection at the base of the tail
and footpads with 60 ? g peptide emulsified in IFA. After
10 days, animals were killed and lymph node cells removed.
Lymphocytes were then plated on 96-well plates at 8×105
cells/well with culture medium alone, or with serial dilutions
of peptide in the same medium to a final volume of 0.25 ml.
Supernatants (50 ? l) were removed 24 h later to measure
IL-2, and 48 h later for IFN- + and IL-4.
4.5 Measurement of cytokine production
IL-2 was measured using a CTLL bioassay as described
[28]. IFN- + production was measured by ELISA (Genzyme,
Cambridge, MA) according to manufacturer’s instructions.
IL-4 was measured by CT4S bioassay (kindly provided by
Drs. W. E. Paul and G. J. Watson, National Institutes of
Health, Bethesda, MD) as described [12].
4.6 Tumor challenge experiments
Animals were immunized with different combinations of pep-
tides in adjuvant or adjuvant alone as described above. They
were challenged by s.c. injection on the right flank with
5×105 CT26 tumor cells at different time points. Tumor size
was expressed as the square value of the smallest diameter
of the tumor, times the value of its largest diameter. Mice
were killed when tumor size reached a volume greater than
10 cm3. To study the efficacy of peptide immunizations in
the development of pulmonary tumor metastases, mice
were challenged i.v. with 1×105 CT26 tumor cells and killed
20 days after challenge. Metastases were counted under the
microscope following injection of 50 ? l India ink 5 min before
their sacrifice.
In some experiments mice were depleted of CD4+ or CD8+
cells by i.p. injection of 0.3 mg anti-CD4 or anti-CD8 anti-
bodies (obtained from rat anti-mouse hybridomas GK 1.5
and H35.17.2, respectively) on days –1, 0, 1, 6 and 10 as
previously described [29], being day 0 the day of peptide
immunization. The efficiency of depletions was assessed by
flow cytometry.
4.7 Recognition of CT26 tumor cell lysate by
lymphocytes from peptide-immunized animals
To study recognition of tumor cells by lymphocytes from
peptide-immunized animals, mice were immunized with
peptide as described above, lymph node cells extracted at
day 10, and stimulated in vitro with or without different dilu-
tions of a lysate of CT26 tumor cells. CT26 cells were lysed
by six cycles of freezing and thawing, followed by sonication
and centrifugation. Culture supernatants were collected
after 24–48 h of culture and cytokines measured.
4.8 Statistics
Statistical analysis was carried out to evaluate the therapeu-
tic effect of peptide immunization in established tumors.
Non-normally distributed variables were analyzed by the
Kruskal-Wallis test, followed by Mann-Whitney’s U as a mul-
tiple comparison test. The effect of immunization with differ-
ent peptide combinations was compared with the control
group immunized with IFA alone. Comparison of protection
between groups was analyzed by Exact test according to
Abramson and Gahlinger (Computer Program for epidemiol-
ogists, PEPI Version 4.0).
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